Table 1.

Patient Demographics and Characteristics

Patient No.	Gender	Age	Stage	Metastasis Status	Gene Profile	PFS (Months)	Response
1	Male	68	IV	Pleural	c-Met (+,15%)	1	PD
2	Female	45	IV	Brain	c-Met (+,25%)	4	PR
3	Male	56	IV	Pleural	c-Met (+,40%)	3	SD
4	Male	48	IV	Liver	EGFR wt	6	PR
5	Female	64	IV	Liver	EGFR del19	4	SD
6	Female	61	IV	Pleural	EGFR wt	6	PR
7	Male	58	IV	Lung	EGFR L858R	3	SD
8	Male	65	IV	Liver	EGFR L858R	5	PR
9	Male	57	IV	Liver	c-Met (+,40%)	1	PD
10	Male	63	IV	Liver	c-Met (+,35%)	1	PD
11	Female	53	IV	Lung	EGFR wt	1	PD
12	Female	36	IV	Pleural and bone	EGFR wt	7	PR
13	Male	61	IV	Lung and pleural	EGFR wt	3	SD
14	Male	70	IV	Pleural	EGFR wt	2	SD
15	Female	63	IV	Pleural	EGFR L858R	5	PR
16	Female	48	IV	Lung and bone	EGFR wt	2	SD
17	Male	62	IV	Bone	EGFR L858R	3	SD
18	Male	65	IV	Brain	c-Met (+,30%)	2	SD
19	Female	61	IV	Bone	EGFR L858R	3	SD
20	Female	56	IV	Brain and bone	EGFR wt	2	SD

PFS, progression free survival; EGFR, epithelial growth factor receptor; wt, wild type; SD, stable disease; PR, partial response; PD, progressive disease.